TY - JOUR
T1 - Impact of gender, depression severity and type of depressive episode on efficacy and safety of escitalopram
T2 - an observational study on major depressive disorder patients in southern India
AU - Mandal, Tatiyana
AU - Bairy, Laxminarayana Kurady
AU - Sharma, Podila Satya Venkata Narasimha
AU - Valaparla, Vijaya Lakshmi
N1 - Funding Information:
We sincerely acknowledge the assistance provided by Dr. Amritavarshini R and Dr. Linda Thomas from the Department of Psychiatry, KMC, Manipal, during data collection. We are thankful to Dr. Smita Shenoy, Department of Pharmacology, KMC, Manipal, and Dr. Ravindra Munoli, Department of Psychiatry, KMC, Manipal, for their valuable inputs on the study.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Background: Antidepressant response is a complex trait influenced by clinical, demographic and genetic factors. Objectives: To explore the influences of baseline depression severity, gender and type of depressive episode on efficacy and safety of escitalopram (10–20 mg/day) in South Indian patients with major depressive disorder (MDD). Methods: The study was conducted on 18–65-year-old patients (n = 151) suffering from a first or recurrent episode of MDD with a 17-item Hamilton Depression Rating Scale (HDRS-17) score of ≥ 18 at baseline. Efficacy assessments were done using HDRS-17, Montgomery-Asberg Depression Rating Scale (MADRS), and Clinical Global Impression (CGI) at baseline and weeks 4, 8 and 12. Patients were monitored for adverse drug reactions (ADRs). Clinical outcomes were compared among various groups based on gender, type of depressive episode (first or recurrent episode) and baseline HDRS-17 scores (moderate depression—score between 17 and 23; severe depression—score ≥ 24). Results: Among the 148 subjects who completed the 12-week study, 43.9% and 42.6% achieved response and remission, respectively. The decline in HDRS-17 and MADRS scores from baseline was significant (p value < 0.05) at all follow-up visits and a similar pattern was seen with CGI. Efficacy outcomes were better in the moderate baseline depression group compared with severe depression. There were no associations of efficacy with gender and type of depressive episode. A total of 247 adverse drug reactions (ADR) were reported and 119 (80.41%) subjects experienced at least one ADR during the study period. No serious ADR was reported. Male patients experienced more ADRs compared with females. The safety profile of escitalopram was similar across various groups based on baseline depression severity and type of depressive episode. Conclusion: The study revealed that escitalopram is efficacious in south Indian MDD patients with a favourable safety profile. The efficacy was influenced by baseline depression severity whereas more ADRs were reported by male patients.
AB - Background: Antidepressant response is a complex trait influenced by clinical, demographic and genetic factors. Objectives: To explore the influences of baseline depression severity, gender and type of depressive episode on efficacy and safety of escitalopram (10–20 mg/day) in South Indian patients with major depressive disorder (MDD). Methods: The study was conducted on 18–65-year-old patients (n = 151) suffering from a first or recurrent episode of MDD with a 17-item Hamilton Depression Rating Scale (HDRS-17) score of ≥ 18 at baseline. Efficacy assessments were done using HDRS-17, Montgomery-Asberg Depression Rating Scale (MADRS), and Clinical Global Impression (CGI) at baseline and weeks 4, 8 and 12. Patients were monitored for adverse drug reactions (ADRs). Clinical outcomes were compared among various groups based on gender, type of depressive episode (first or recurrent episode) and baseline HDRS-17 scores (moderate depression—score between 17 and 23; severe depression—score ≥ 24). Results: Among the 148 subjects who completed the 12-week study, 43.9% and 42.6% achieved response and remission, respectively. The decline in HDRS-17 and MADRS scores from baseline was significant (p value < 0.05) at all follow-up visits and a similar pattern was seen with CGI. Efficacy outcomes were better in the moderate baseline depression group compared with severe depression. There were no associations of efficacy with gender and type of depressive episode. A total of 247 adverse drug reactions (ADR) were reported and 119 (80.41%) subjects experienced at least one ADR during the study period. No serious ADR was reported. Male patients experienced more ADRs compared with females. The safety profile of escitalopram was similar across various groups based on baseline depression severity and type of depressive episode. Conclusion: The study revealed that escitalopram is efficacious in south Indian MDD patients with a favourable safety profile. The efficacy was influenced by baseline depression severity whereas more ADRs were reported by male patients.
UR - http://www.scopus.com/inward/record.url?scp=85103852073&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103852073&partnerID=8YFLogxK
U2 - 10.1186/s41983-021-00302-7
DO - 10.1186/s41983-021-00302-7
M3 - Article
AN - SCOPUS:85103852073
SN - 1110-1083
VL - 57
JO - Egyptian Journal of Neurology, Psychiatry and Neurosurgery
JF - Egyptian Journal of Neurology, Psychiatry and Neurosurgery
IS - 1
M1 - 47
ER -
